Press Release: Ventus : Ventus Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating VENT-02, an Oral, Brain-Penetrant NLRP3 Inhibitor, in Parkinson's Disease

WALTHAM, Mass. & MONTREAL--(BUSINESS WIRE)--Ventus Therapeutics, a clinical-stage biopharmaceutical company with two novel small-molecule programs entering Phase 2 development for immunological, inflammatory, and neurological disorders, today announced that the first patient has been dosed in a Phase 2a trial of VENT-02 in patients with mild to moderate Parkinson's disease. VENT-02 is a novel, oral, brain-penetrant inhibitor of NLRP3, a key driver of inflammation and component of the innate imm